Magenta Therapeutics Analysis
Magenta Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Magenta Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Magenta Therapeutics is worth, separate from its market price. There are two main types of Magenta Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Magenta Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Magenta Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Magenta |
Magenta Stock Analysis Notes
About 63.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.54. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Magenta Therapeutics recorded a loss per share of 1.11. The entity had not issued any dividends in recent years. Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Magenta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people. To find out more about Magenta Therapeutics contact Jason DPHIL at 857 242 0170 or learn more at https://www.magentatx.com.Magenta Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Magenta Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Magenta Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Magenta Therapeutics is not yet fully synchronised with the market data | |
| Magenta Therapeutics has some characteristics of a very speculative penny stock | |
| Magenta Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (76.46 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Magenta Therapeutics currently holds about 128.28 M in cash with (67.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.13. | |
| Roughly 63.0% of the company shares are owned by institutional investors |
Magenta Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Magenta Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Magenta Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.14 M.Magenta Therapeutics Outstanding Bonds
Magenta Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Magenta Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Magenta bonds can be classified according to their maturity, which is the date when Magenta Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US55916AAA25 Corp BondUS55916AAA25 | View | |
| US55916AAB08 Corp BondUS55916AAB08 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Magenta Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
| All Next | Launch Module |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Magenta Stock
If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |